Zeolitic Imidazolate Framework Antibody Conjugates in Bioanalytical Applications

05 October 2020, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Improvements in bioanalytical technologies are driven by evolving threats and challenges to the global community. These challenges include emerging diseases, the need for substance screening and increasing environmental pollution. Here, we present a new bioanalytical concept that employs nanosized Metal-Organic Framework (MOF) particles as labels for antibody-based analytical methods, including enzyme-linked immunosorbent assay (ELISA) and lateral flow immunoassay (LFIA). A strategy for covalently linking antibodies to form stable, colloidal Zeolitic Imidazolate Frameworks (ZIFs) conjugates is described. The proof of principle for their use in LFIA is presented. In particular, ZIF-antibody conjugates displayed excellent behaviour in dispersion and good mobility via lateral flow on a solid substrate while retaining full selectivity of the antibody. Moreover, protein aggregation of the antibodies was prevented, suggesting protection against degradation in an exoskeleton-like manner. Our study could inspire future work to address global bioanalytical and diagnostic challenges.

Keywords

metal-organic frameworks (MOFs)
zeolite analogues
antibodies
immunoassays
particulate labels

Supplementary materials

Title
Description
Actions
Title
SI
Description
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.